TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Turn Therapeutics Inc ( (TTRX) ) has provided an announcement.
On October 22, 2025, Turn Therapeutics provided a shareholder update, highlighting progress in its clinical programs and its strategic capital strategy. The company is advancing its phase 2 trial of GX-03 for eczema and developing a thermostable intranasal vaccine. Turn’s direct listing structure and $85 million GEM Global Yield agreement offer flexible financing, potentially reducing future equity offerings.
More about Turn Therapeutics Inc
Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious diseases. The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis, while also pursuing global health initiatives in thermostable vaccine delivery.
Average Trading Volume: 2,310,633
For detailed information about TTRX stock, go to TipRanks’ Stock Analysis page.